In Hodgkin lymphoma, the expression of CD30 and PD-1 has enabled successful immune checkpoint blockade, whereas in non-Hodgkin lymphoma, the mutations of CD20 and BCL2 inform antibody-based and BCL2 inhibitor therapies [152,153]. The gene discussed is BCL2; the disease is non-Hodgkin lymphoma.